## ImmunoGen's Elahere Milestone: First-in-Class ADC Approved for Platinum-Resistant Ovarian Cancer
ImmunoGen achieved a significant regulatory breakthrough as the FDA granted accelerated approval for Elahere (mirvetuximab soravtansine-gynx), marking a major advancement in treating platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. This represents the first FDA-approved antibody-drug conjugate (ADC) specifically targeting folate receptor alpha (FRα) in platinum-resistant ovarian cancer patients who have undergone one to three prior systemic treatment regimen